We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Comprehensive Tumor Profiling Kit Decentralizes and Standardizes Oncology Testing

By LabMedica International staff writers
Posted on 05 Sep 2025

Cancer remains one of the leading global health burdens, with accurate and timely tumor profiling critical to guiding treatment decisions. More...

Traditional approaches often struggle to capture the full range of genetic alterations that drive disease, limiting precision medicine strategies. Now, a comprehensive genomic profiling panel for the early and reliable detection of clinically relevant tumor gene changes reveals clinically actionable information for therapy selection.

Geneseeq Technology’s (Toronto, Canada) GeneseeqPrime NGS Tumor Profiling Assay provides information on clinically actionable genomic alterations and their associated targeted therapy. This next-generation sequencing (NGS) test analyzes DNA from FFPE tumor tissue to detect alterations across 425 cancer-related genes, including SNVs, indels, amplifications, translocations, MSI, and TMB. Delivered as a ready-to-use kit, it enables decentralized adoption with standardized workflows across oncology laboratories.

Analytical and clinical validation studies across multiple U.S. clinical laboratories demonstrated high sensitivity, specificity, and reproducibility for the GeneseeqPrime assay. The assay is paired with GENESIS by Geneseeq, a proprietary bioinformatics pipeline and reporting system validated in CLIA/CAP-accredited labs. Together, these components provide a consistent data analysis and reporting framework, supporting its intended clinical use in oncology.

The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for GENESEEQPRIME NGS Tumor Profiling Assay, strengthening its role in biomarker-driven drug development, multi-regional clinical trials, and future companion diagnostics. The assay supports globally harmonized standards, adding to CE-IVD marking in Europe and NMPA approval in China. This milestone positions Geneseeq to expand patient access to precision oncology, with additional applications in standardized testing and future CDx strategies worldwide.

“FDA 510(k) clearance of GeneseeqPrime marks a major milestone for Geneseeq and for the broader oncology community,” said Xue Wu, PhD, CEO of Geneseeq Technology. “By enabling laboratories to deliver high-quality genomic profiling locally on a standardized, regulatory-cleared platform, we are expanding patient access to precision medicine and supporting innovation in cancer care worldwide.”

Related Links:
Geneseeq Technology Inc.


Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Collection and Transport System
PurSafe Plus®
ESR Analyzer
TEST1 2.0
Gold Member
Hematology Analyzer
Medonic M32B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Technology

view channel
Image: The SWITCH hybrid pipette is designed to simplify and accelerate pipetting tasks (Photo courtesy of INTEGRA)

Hybrid Pipette Combines Manual Control with Fast Electronic Aliquoting

Manual pipettes offer the control needed for delicate tasks such as mixing or supernatant removal, but typically fall short in repetitive workflows like aliquoting. Electronic pipettes solve this problem... Read more

Industry

view channel
Image: Lunit and Agilent Technologies are collaborating to develop AI-powered companion diagnostics. (Photo courtesy of Lunit)

Lunit and Agilent Partner to Develop AI-Powered Cancer Diagnostics

Biomarker testing plays a critical role in precision oncology, guiding tailored therapies for patients. However, current methods often rely heavily on manual interpretation, which can introduce variability... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.